company background image
RTSL

Rapid Therapeutic Science Laboratories OTCPK:RTSL Stock Report

Last Price

US$2.40

Market Cap

US$18.6m

7D

21.8%

1Y

-70.9%

Updated

12 Aug, 2022

Data

Company Financials
RTSL fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health2/6
Dividends0/6

RTSL Stock Overview

Rapid Therapeutic Science Laboratories, Inc.

Rapid Therapeutic Science Laboratories, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Rapid Therapeutic Science Laboratories
Historical stock prices
Current Share PriceUS$2.40
52 Week HighUS$12.50
52 Week LowUS$1.62
Beta-13.38
1 Month Change13.74%
3 Month Change-40.00%
1 Year Change-70.91%
3 Year Changen/a
5 Year Change-88.56%
Change since IPO-82.55%

Recent News & Updates

Shareholder Returns

RTSLUS Medical EquipmentUS Market
7D21.8%1.9%3.2%
1Y-70.9%-19.1%-10.1%

Return vs Industry: RTSL underperformed the US Medical Equipment industry which returned -20.3% over the past year.

Return vs Market: RTSL underperformed the US Market which returned -11.7% over the past year.

Price Volatility

Is RTSL's price volatile compared to industry and market?
RTSL volatility
RTSL Average Weekly Movementn/a
Medical Equipment Industry Average Movement9.4%
Market Average Movement7.7%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: Insufficient data to determine RTSL's volatility over the past 3 months.

Volatility Over Time: Insufficient data to determine RTSL's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
20138Don Schmidthttps://www.rtslco.com

Rapid Therapeutic Science Laboratories, Inc. operates as a biotech company. The company engages in the aerosol delivery of non-psychoactive cannabinoids to the blood stream for treatment of chronic pain, post-traumatic stress disorder, insomnia, surgery recovery, and other ailments. It offers pressurized meter dose inhaler, a device that delivers a measured amount of aerosolized inhalant in a mist to the lungs; sublingual oral spray devices; and water-soluble cannabidiol and cannabigerol isolates under the nhaler brand.

Rapid Therapeutic Science Laboratories, Inc. Fundamentals Summary

How do Rapid Therapeutic Science Laboratories's earnings and revenue compare to its market cap?
RTSL fundamental statistics
Market CapUS$18.60m
Earnings (TTM)-US$3.91m
Revenue (TTM)US$534.00

Over9,999x

P/S Ratio

-4.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
RTSL income statement (TTM)
RevenueUS$534.00
Cost of RevenueUS$200.00
Gross ProfitUS$334.00
Other ExpensesUS$3.91m
Earnings-US$3.91m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.51
Gross Margin62.55%
Net Profit Margin-732,937.83%
Debt/Equity Ratio-94.4%

How did RTSL perform over the long term?

See historical performance and comparison